Fennec Pharmaceuticals Ord Shs T.FRX

Alternate Symbol(s): FENC

Healthcare Biotechnology

Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on its product candidate PEDMARK. It sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is a Food and Drug Administration approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. It is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase 3 clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. It has established Fennec HEARS, a single source program designed to connect PEDMARK patients.

TSX:FRX - Post by User

Fennec Pharmaceuticals Ord Shs

Bullboard Posts

Post by Brinkleyon Jul 20, 2005 6:55pm

222 Views

Post# 9301633

Reverse split

they just announced a 5 - 1 reverse split. Now that we have some upward momentum it should be positive. this will give us a price of $2.25 per share. Hopefully we will get more attention from the bigger buyers. Biotech is on its way back up. Growth is starting to be back in favour the deal with GSK gives a lot of credibility to us I'm excited about the next few months

Bullboard Posts

BMO evolves InvestorLine with enhanced tools for options trading